Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
vaginal four-strain live Lactobacillus capsule
- Development stage
- Phase 3
- Lead developer
- Zhejiang Wansheng Pharmaceutical
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Vaginal
01
Overview
Vaginal four-strain live Lactobacillus capsule is a live biotherapeutic product (LBP) developed for the treatment and prevention of recurrence of bacterial vaginosis (BV). The formulation consists of four specific strains of Lactobacillus: *L. crispatus*, *L. gasseri*, *L. jensenii*, and *L. rhamnosus*. These strains are natural inhabitants of a healthy vaginal microbiome and are intended to restore a Lactobacillus-dominant environment following antibiotic therapy. The drug works by re-establishing the vaginal microbiota, producing lactic acid to maintain a low vaginal pH (typically <4.5), and secreting antimicrobial substances such as hydrogen peroxide and bacteriocins to inhibit the growth of anaerobic pathogens like *Gardnerella vaginalis*. It is currently being evaluated in Phase III clinical trials in China, sponsored by Peking Union Medical College Hospital and manufactured by Zhejiang Wansheng Pharmaceutical.
- Other names
- Vaginal Four-strain Live Lactobacillus Capsules阴道用四联乳杆菌活菌胶囊
Beyond the preview
Go deeper on vaginal four-strain live Lactobacillus capsule.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on vaginal four-strain live Lactobacillus capsule.